CRISPR-Cas9
The advent of CRISPR-Cas9 technology has marked a milestone in the field of genome editing, by treating diseases and advancing biotechnology. This powerful tool, developed from a natural bacterial immune system, allows for precise modifications to DNA.
1987: Japanese scientist Yoshizumi Ishino first identified clustered regularly interspaced short palindromic repeats (CRISPR) in E. coli, laying the foundation for the technology.
2013: The first use of CRISPR in human cells is reported, opening up possibilities for therapeutic applications
2015: The first CRISPR clinical trial is approved in China for treating lung cancer.
2016: The first CRISPR clinical trial in the US is approved for treating cancer.
2020: Doudna and Charpentier were awarded the Nobel Prize for their contributions to the development of CRISPR-Cas9.
2018: The first gene-edited babies were announced by Chinese scientist Jiankui, sparking ethical concerns and calls for a moratorium on inheritable genomic manipulations.
2020: The first patient received gene editing therapy with CRISPR-Cas9 directly administered into the body.
2021: CRISPR is used to treat a genetic disorder called transthyretin amyloidosis in a clinical trial
2022: Positive results are reported from a Phase II/III trial using CRISPR to treat sickle cell disease, bringing a potential therapy closer to approval.
2022: A small clinical trial showed promising results for using CRISPR-Cas9 to edit immune cells and enhance their capacity to destroy cancer cells.
2023: CRISPR Therapeutics and Vertex Pharmaceuticals plan to submit a Biologics License Application for a CRISPR-based treatment for sickle cell disease and beta-thalassemia, potentially leading to the first approval of a CRISPR therapy.
CRISPR-Cas9: A Versatile Tool for Genome Editing
CRISPR-Cas9 operates by utilizing a guide RNA to direct the Cas9 enzyme to specific locations in the genome, where it can cut the DNA, allowing for the insertion, deletion, or alteration of genetic material. This precision has made it an invaluable asset in various fields, including agriculture, where it enhances crop resilience, and medicine, where it holds promise for treating genetic disorders such as sickle cell anemia and cystic fibrosis.
Saint Mary's College-Gujranwala: Educating the Next Generation of Biotechnologists
At Saint Mary's College-Gujranwala, we take pride in incorporating CRISPR-Cas9 technology into our BS Biotechnology program. Our curriculum not only covers the theoretical aspects of genome editing but also emphasizes in depth teaching, equipping students with the skills needed to navigate this rapidly evolving field. By fostering a deep understanding of CRISPR.
Ethical Considerations and the Future of CRISPR-Cas9
The potential of CRISPR-Cas9 extends beyond mere gene editing; it represents a paradigm shift in our ability to manipulate the genetic code. The scientific community is tasked with ensuring that advancements are made responsibly, balancing innovation with ethical integrity. In conclusion, CRISPR-Cas9 technology stands as a beacon of hope in the fight against genetic diseases, and institutions like Saint Mary's College of Medical & Advance Studies-Gujranwala are at the forefront of this revolution. By educating the next generation of biotechnologists.
Saint Mary's College to Host Seminar on CRISPR-Cas9 Technology:
The Department of Biochemistry and Biotechnology at Saint Mary's College of Medical & Advance Studies recently held a one-day seminar dedicated to the revolutionary CRISPR-Cas9 technology. Under the guidance of Ms. Hadiqa Faiz ul Rasul, HoD, the event explored significant advancements in gene editing. The college was honored to have Mr. Shoaib Hasan, a former faculty member currently working at the University of Lahore, as the esteemed guest speaker. His expertise in CRISPR-Cas9 provided attendees with valuable insights. Supported by faculty members Dr. Khizra Bano, Ms. Rafia Sameen, and Ms. Syeda Safina Zanib, the seminar took place at Aster's Hall on the Saint Mary's College campus. Participant students engaged with experts and enhanced their knowledge of the transformative impact of CRISPR-Cas9 technology on biotechnology.
Comments